Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.

By: Carreyrou, John [author.]
Material type: TextTextPublisher: New York : Alfred A. Knopf, 2018Copyright date: �2018Edition: First editionDescription: x, 339 pages ; 25 cmContent type: text Media type: unmediated Carrier type: volumeISBN: 9781524731656; 152473165XOther title: Secrets and lies in a Silicon Valley startupSubject(s): Holmes, Elizabeth, 1984- | Theranos (Firm) -- History | Hematologic equipment industry -- United States | New business enterprises -- Corrupt practices -- United States -- Cases | Securities fraud -- United States -- CasesGenre/Form: History.DDC classification: 338.7/681761 LOC classification: HD9995.H423 | U627 2018
Contents:
A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\Day -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue.
Summary: In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.
List(s) this item appears in: New York Times Best Seller List NonFiction | Nonfiction Best Sellers/ Endcap Display Downtown
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
Item type Current location Collection Call number Status Date due Barcode Item holds
Book Book Downtown Branch
Adult non-fiction
Adult non-fiction 338.7681 CAR (Browse shelf) Checked out 07/24/2020 31562016934905
Book Book Madison Branch
Adult non-fiction
Adult non-fiction BUS 338.7681 CAR (Browse shelf) Available 31562016902951
Book Book Monrovia Branch
Adult non-fiction
Adult non-fiction 338.7681 CAR (Browse shelf) Available 31562016985089
Total holds: 0

Includes bibliographical references (pages 305-324) and index.

A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\Day -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue.

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.

There are no comments on this title.

to post a comment.

Other editions of this work

Bad blood by Carreyrou, John. ©2018
Bad blood by Carreyrou, John. ©2018
Bad blood by Carreyrou, John, ©2018

915 Monroe Street, Huntsville, AL 35801 | Phone: (256) 532-5940 | Circulation & Renewals: (256) 532-5984 | Contact the Library | Privacy Policy

Powered by Koha